Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Target Price at $37.56

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has earned a consensus recommendation of “Moderate Buy” from the nineteen analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $37.56.

NTLA has been the topic of several research analyst reports. BMO Capital Markets lowered their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, January 10th. Barclays lowered their target price on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Morgan Stanley cut Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $56.00 to $11.00 in a report on Monday, January 27th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Finally, Citigroup lifted their target price on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 28th.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of NTLA. State Street Corp lifted its position in Intellia Therapeutics by 17.9% in the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after acquiring an additional 780,754 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Intellia Therapeutics by 125.2% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company’s stock valued at $1,411,000 after purchasing an additional 67,276 shares in the last quarter. Avanza Fonder AB purchased a new stake in shares of Intellia Therapeutics during the fourth quarter valued at $421,000. Barclays PLC increased its holdings in Intellia Therapeutics by 17.7% in the 3rd quarter. Barclays PLC now owns 292,795 shares of the company’s stock worth $6,017,000 after buying an additional 44,022 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Intellia Therapeutics by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after buying an additional 49,367 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $7.23 on Tuesday. The firm’s fifty day moving average price is $8.93 and its two-hundred day moving average price is $12.28. The company has a market cap of $748.43 million, a P/E ratio of -1.33 and a beta of 2.23. Intellia Therapeutics has a one year low of $5.90 and a one year high of $28.18.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.